Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedicitumomab (RC48) in Salivary Gland Ductal Carcinoma
NCT05898373Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 2, randomised, open-label trial of disitamab vedotin in salivary duct carcinoma (SDC) (4 arms), sponsored by Peking Union Medical College. Primary endpoint: Objective Response Rate at 8 weeks. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
salivary duct carcinoma (SDC)
Beyond the preview
Go deeper on NCT05898373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05898373.